Insulet Corp (PODD) stock
Close on Nov 11, 2026Market cap $10.41BP/E 24.4Yield –
Insulet Corp grew revenue 26.5% to $3.19B over the twelve months to Sep 30, 2026. Operating income rose 34.6% to $587.90M, moving the operating margin from 17.3% to 18.4%. Free cash flow was $260.00M, down 38.6% from a year earlier. At the latest close the market valued the company at $10.41B, 24.4 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $10.41B
- P/E ratio
- 24.4
- Price to sales
- 3.26
- Price to book
- 6.59
- Dividend yield
- –
- Free cash flow yield
- 2.50%
Fundamentals
- Revenue
- $3.19B
- Net income
- $428.80M
- EPS, diluted
- $6.14
- Free cash flow
- $260.00M
- Book value per share
- $22.72
- Diluted shares
- 69M
Trading
- Next earnings
- Feb 17, 2027 (estimated, before the open)
- Previous close
- $148.06
- Open
- $146.20
- Day's range
- $146.15 – $150.35
- Volume
- 1,042,744
- Average volume (20 days)
- 1,400,559
- Index membership
- S&P 500 (since Mar 2023), Russell 1000, Russell 3000
- Beta (5 years)
- 0.88
- 52-week range
- $126.40 – $354.88
- RSI (14 days)
- 53.1
- Volatility (1 year)
- 46.2%
- Relative volume
- 0.65×
- WACC
- 8.9%
On 3 of our idea lists: Undervalued and financially sound, Strong quarter, insiders buying, Fallen quality
Index membership is inferred from the holdings of funds that track each index (VOO, IVV, SPYM, IWB, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PODD | S&P 500 | Difference | PODD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +10.9% | -2.4% | +13.3 pts | ||
| 3 months | +3.7% | -1.2% | +4.8 pts | ||
| Year to date | -47.2% | +12.3% | −59.5 pts | ||
| 1 year | -54.0% | +12.4% | −66.5 pts | ||
| 3 years | -3.3% | +78.8% | −82.1 pts | -1.1% | +21.4% |
| 5 years | -52.3% | +75.2% | −127.5 pts | -13.8% | +11.9% |
| 10 years | +322.4% | +311.1% | +11.3 pts | +15.5% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Insulet filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Update
About Insulet
Surgical & Medical Instruments & Apparatus
Insulet Corporation develops, manufactures, and sells proprietary continuous insulin delivery devices designed for individuals with insulin-dependent diabetes. Its core offering is the Omnipod tubeless platform, which includes the Omnipod 5 Automated Insulin Delivery System, the Omnipod DASH Insulin Management System, and the legacy Classic Omnipod. In addition to insulin management systems, the company produces drug delivery pods utilized in Amgen's Neulasta Onpro kits to assist chemotherapy patients. Insulet serves individuals with type 1 and type 2 diabetes through commercial distribution partners, independent wholesalers supplying pharmacy networks, healthcare organizations, and direct consumer channels.
Company profile, executives and historyInsulet stock: common questions
What is Insulet's stock price?
PODD closed at $150.03 on Nov 11, 2026, up 1.33% on the day. Over the past 52 weeks it traded between $126.40 and $354.88.
What is Insulet's market cap?
Insulet was worth $10.41B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PODD's P/E ratio?
PODD trades at 24.4 times earnings, based on diluted earnings per share of $6.14 over the twelve months to Sep 30, 2026.
How much revenue does Insulet make?
Insulet reported revenue of $3.19B for the twelve months to Sep 30, 2026, up 26.5% from a year earlier.
Does Insulet pay a dividend?
No. Insulet has not paid a cash dividend over the last twelve months.
When does Insulet report earnings next?
Insulet is expected to report Q4 FY2026 results on Feb 17, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PODD stock performed over the past year?
Including dividends, PODD returned -54.0% over the past year, against +12.4% for the S&P 500.
How many PODD shares are sold short?
5M shares were sold short at the latest FINRA report, 7.72% of the float, or 4.3 days of average trading volume.
Who are Insulet's competitors?
Companies most similar to Insulet by business, industry and size include MMED, TNDM, DXCM, ICUI, TFX.
See a number that looks wrong?